|
Patent landscape, scope, and claims: |
United States Patent 9,012,484 (luliconazole monoclinic P21 crystal composite): scope, claim boundaries, and US landscape
US Patent 9,012,484 is directed to a specific polymorph-like crystalline form of luliconazole embedded or associated with short-chain alcohol, defined by hard crystallographic parameters plus a defined alcohol loading window (100 to 10,000 ppm). It then expands scope to (i) an API containing that crystal composite and (ii) pharmaceutical preparations and antifungal treatment methods using an administration and dosing envelope, including external use and nail application. The independent product claim (claim 1) is the central enforceable anchor: later claims largely remain tethered to the same crystal composite definition.
What is claimed in the independent product claim (claim 1)?
Claim 1 defines a “crystal composite consisting of luliconazole” that has two essential technical requirements:
1) Composition requirement: luliconazole + short-chain alcohol at a ppm range
- Luliconazole as the crystal component
- Short chain alcohol with:
- Number of carbon atoms: 1 to 4
- Alcohol loading: 100 to 10,000 ppm with respect to the total amount of the crystal composite
- Short chain alcohol examples in dependent claims:
This is a compositional limitation that narrows claim scope versus broad “luliconazole crystals” or general co-crystals. The alcohol is not optional and is not unlimited: it is numerically bounded by both chain-length and ppm.
2) Crystal identity requirement: monoclinic P21 with specified unit-cell and refinement metrics
The crystal is characterized by:
- Crystal system: monoclinic
- Space group: P21
- Lattice constants:
- a = 9.0171(9) Å
- b = 8.167(1) Å
- c = 10.878(1) Å
- β = 95.917(9)°
- R factors:
In practice, this kind of crystallographic recitation is used to lock enforceability to a particular solid form, because the claims do not merely say “monoclinic P21”; they define a specific unit cell and refinement quality. Competitors trying to design around by shifting polymorph form, lattice parameters, space group, or refinement outcomes have clearer technical footing than competitors trying to avoid a generic “crystal composite.”
What do the dependent claims add?
Alcohol identity and process context
- Claim 2: alcohol is ethanol
- Claim 3: the crystal is produced by:
- recrystallizing with the short chain alcohol (alcohol may contain water),
- then drying, and
- adding alcohol if necessary
This claim ties alcohol association to a specific manufacturing logic: recrystallization with the alcohol (potentially aqueous), drying, and re-dosing alcohol if needed. It matters because it gives the patentee additional, process-linked hooks when defending product-by-process disputes.
API and formulation use
- Claim 4: Active pharmaceutical ingredient containing the crystal composite of claim 1
- Claim 5: method for producing a pharmaceutical preparation including dissolving the crystal in a solvent
Claim 5 is narrower than it looks: it does not cover “making formulations generally,” it covers a “step of dissolving, in a solvent” the specified crystal composite, which can be a common step in preparing topical, suspension, or solution-based products. The claim still depends on having the defined crystal composite.
Antifungal treatment methods
- Claim 6: method of treating fungal infection by administering an effective amount of a composition comprising the crystal of claim 1 to a subject in need
- Claim 7: fungal infection caused by:
- tinea pedis
- tinea corporis
- tinea versicolor
- tinea unguim
- Claim 8: fungal infection selected from:
- athlete’s foot
- candidiasis
- trichophytosis of hard keratin
- Claim 9: fungal infection is a dermatomycosis
- Claim 10: luliconazole dose 0.01 to 1 g per day
- Claim 11: composition applied externally
- Claim 12: composition applied to a nail
These dependent claims build a “use-case portfolio” from general antifungal treatment to specific dermatophyte and nail-related indications, with an administration route (external), and a dosing band.
Specific manufacturing procedure for the luliconazole crystal
- Claim 13: method of preparing the luliconazole crystal of claim 1:
- (a) crystallizing luliconazole from ethyl acetate + n-hexane
- (b) recrystallizing with ethanol
- (c) collecting crystals
- (d) drying
- Claim 14: ethanol contains water
- Claim 15: API containing the crystal composite of claim 1 and “a substance within a range permitted as the active pharmaceutical ingredient”
Claim 13 is a classic “narrow method” claim. It matters for enforcement against manufacturers whose process matches the specific solvent system (ethyl acetate/n-hexane then ethanol recrystallization).
How broad is the claim scope in practice?
Product scope (claims 1 and 4)
Very narrow on identity, broader on alcohol identity within constraints. The crystal composite must match the defined crystallographic parameters and must include 100 to 10,000 ppm of short-chain alcohol (1 to 4 carbons). Within that, the alcohol may vary (claim 2 locks to ethanol). That means:
- Design-around by different polymorph: likely the strongest route. If lattice parameters or space group differ, the product may fall outside claim 1.
- Design-around by different alcohol association: shifting the ppm below 100 ppm or above 10,000 ppm can also move outside the literal range.
- Design-around by non-short-chain alcohol: using alcohols with >4 carbons would likely fall outside claim 1, unless the product still contains a 1-4 carbon alcohol at the required ppm window.
Method scope (claims 5, 13, 6-12)
- Formulation manufacturing: dissolving the defined crystal in a solvent is common; claim 5 is not limited to a particular dosage form beyond being a “pharmaceutical preparation.”
- Treatment: the claims are tied to administering a composition containing the crystal composite. A key risk for generic and alternative-manufacture entrants is “form” and “use” rather than only “formulation ingredients,” because claim 6-12 can attach if the product contains the protected crystal form.
- Process manufacturing: claim 13 creates a direct infringement pathway against manufacturers who use the solvent sequence and ethanol recrystallization.
What are the strongest enforcement targets?
- API purchasers and finished-dose/topical product suppliers that use or source luliconazole solids matching the crystal identity and alcohol ppm window.
- Solid-form manufacturers using the specific solvent systems:
- crystallization from ethyl acetate/n-hexane
- recrystallization with ethanol (with or without water per claim 14)
- Topical/nail antifungal product makers whose claimed or marketed use aligns with dermatomycoses and external nail application and whose product contains the protected crystal form.
Where are the clearest weak points for challengers?
Without needing to speculate beyond the claim language, the scope has built-in vulnerability to disputes around:
- Whether a competitor’s solid matches the required crystallographic identity (space group, unit cell parameters, and refinement metrics).
- Whether the competitor’s solid has 100 to 10,000 ppm of a 1 to 4 carbon alcohol relative to the total crystal composite.
- Whether the competitor’s route truly “contains” the crystal composite as claimed (crystal identity is product-defining, not just compositional).
- Whether use and dosing fall inside claim 6-12 if a competitor targets different indications, routes, or dosing regimens outside the recited parameters.
US patent landscape implications (how this claim structure tends to map to competitive strategy)
A claim set built around a crystallographic-defined solid form and a defined alcohol loading typically creates three land-grabs in the US market:
-
Solid-form moat around a known active (luliconazole)
Even if luliconazole itself is known, a later crystal composite can carve out exclusivity on the specific solid form used in therapeutics.
-
Secondary moat in manufacturing process claims
Solvent system recitation in claim 13 can be used as a litigation lever against process-matched competitors.
-
Use-claims moats in topical and nail antifungals
The treatment method claims (dermatomycosis, tinea subset, nail application, and dose band) can support enforcement even when formulation excipients differ, as long as the protected crystal composite is present.
Key practical read-through for stakeholders
- If you are an abbreviated applicant or alternative manufacturer: the most immediate non-infringement question is whether your solid state form is the same under crystallographic testing and whether your alcohol content fits the ppm window.
- If you are a formulator: the key question is not only dissolution and bioavailability, it is whether sourcing your API crystallization step yields the claimed crystal composite, including residual alcohol or alcohol incorporated at the ppm level.
Claim-by-claim scope table (what each claim locks in)
| Claim |
What is required (hard limitations) |
Scope impact |
| 1 |
Luliconazole crystal composite + short-chain alcohol (C1-4) at 100 to 10,000 ppm; crystal defined as monoclinic, P21, with a=9.0171(9) Å; b=8.167(1) Å; c=10.878(1) Å; β=95.917(9)°; R=0.046; Rw=0.047 |
Core identity gate; tight solid-form limitation |
| 2 |
Alcohol is ethanol |
Narrow subset for products using ethanol-associated composite |
| 3 |
Production includes recrystallizing with alcohol (may contain water), drying, then adding alcohol if needed |
Process-linked manufacturing hook |
| 4 |
API contains claim 1 crystal composite |
Product enforcement at API level |
| 5 |
Pharmaceutical prep method includes dissolving the claim 1 crystal |
Formulation manufacturing hook |
| 6 |
Administer effective amount of composition comprising claim 1 crystal |
Treatment infringement depends on composition containing crystal |
| 7 |
Infection caused by tinea pedis/corporis/versicolor/unguim |
Indication narrowing inside claim 6 |
| 8 |
Infection selected from athlete’s foot/candidiasis/trichophytosis of hard keratin |
Additional indication narrowing |
| 9 |
Infection is dermatomycosis |
Broadens within fungal dermatology category |
| 10 |
Luliconazole dose 0.01 to 1 g/day |
Dose band limitation |
| 11 |
Applied externally |
Route limitation |
| 12 |
Applied to a nail |
Device/target sub-route limitation |
| 13 |
Crystallize from ethyl acetate + n-hexane, recrystallize with ethanol, collect, dry |
Narrow process claim matching specific solvent workflow |
| 14 |
Ethanol contains water |
Narrows further subset |
| 15 |
API includes claim 1 crystal composite plus a substance within range permitted as API |
Adds formulation latitude under permitted range |
Key Takeaways
- US 9,012,484 is built on a defined luliconazole crystal composite: monoclinic P21 with specified unit-cell parameters and refinement metrics, plus 100 to 10,000 ppm of C1-4 short-chain alcohol.
- The strongest literal scope is claim 1, which controls claims 2-4 and is incorporated into method claims 5-6 and the treatment/use claims 6-12.
- Process alignment to claim 13 (ethyl acetate/n-hexane crystallization, then ethanol recrystallization, then drying) is a clear enforcement pathway for manufacturers.
- The method claims create a topical and nail-use enforcement envelope, with an included dosing range (0.01 to 1 g/day) and specified fungal categories (tinea subset, dermatomycosis, candidiasis, and hard keratin trichophytosis).
FAQs
-
Does claim 1 require ethanol specifically?
No. Claim 1 requires a short-chain alcohol with 1 to 4 carbon atoms at 100 to 10,000 ppm. Claim 2 specifies ethanol.
-
What is the enforceability hinge for competitors: the alcohol amount or the crystallography?
Claim 1 requires both. A product must meet the crystal definition (monoclinic P21 with specific lattice and R factors) and include the alcohol ppm and chain-length requirement.
-
Can a competitor avoid infringement by changing solvents used in manufacturing?
Changing solvents can help avoid process claim 13, but does not avoid product claims if the final API still contains the claimed crystal composite defined in claim 1.
-
Do the treatment claims cover only toenail and fingernail?
The claims specify external application and application to a nail (claim 12), which targets nail-directed use, while remaining tied to the composition containing the claim 1 crystal composite.
-
What dosing window is explicitly claimed for treatment methods?
Claim 10 states luliconazole is administered at 0.01 to 1 g per day.
References
[1] U.S. Patent 9,012,484 (luliconazole crystal composite; claims as provided in prompt).
More… ↓
⤷ Start Trial
|
